PENUMBRA INC
PENNYSETrading Snapshot
- Day Range
- $316.35 β $321.15
- 52-Week Range
- $221.26 β $362.41
- Volume (shares)
- 851,285
- Avg Volume (shares)
- β
- Shares Outstanding
- 39.4M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $1.40B
- Last Q Revenue
- $390M
- P/E Ratio
- 79.7
- P/S Ratio
- 8.5x
- EPS (TTM)
- $4.07
- Dividend Yield
- β
- Dilution (1yr)
- +0.3%
PENUMBRA INC
PENAbout PENUMBRA INC
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective ALAMEDA, Calif., Oct. 20

Penumbra (NYSE:PEN) Stock Breaks Above 50-Day Moving Average β Should You Sell?
Penumbra, Inc. (NYSE: PEN - Get Free Report)'s share price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $321.17 and traded as high as $322.80. Penumbra s

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients' everyday recovery ALAMEDA, Calif., Oct. 6, 2026 /

IART vs. PEN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for t

Penumbra (NYSE:PEN) Stock Price Breaks Below Fifty Day Moving Average β Whatβs Next?
Penumbra, Inc. (NYSE: PEN - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $321.74 and traded as low as $318.14. Penumbra shares

IART or PEN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two companies is the best option for those looking fo